- Category: Experimental HCV Drugs
- Published on Thursday, 28 January 2016 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.